… Platelet function has been linked to both oncogenesis and immune evasion. We studied the
association between the change in mean platelet volume (MPV), platelet count, survival, and …

… This study aims to investigate the mean platelet volume to lymphocyte ratio (MPVLR), as
measured by a hemogram test, and median overall survival (mOS) in patients with cancer …

… of pembrolizumab, nivolumab, and ipilimumab on platelet aggregation … Perhaps this feature
alone or in combination with other … its special off-target interaction with aggregating platelets. …

… Immunotherapy combined with chemotherapy and immunotherapy alone accounted for
76.0% and 24.0% of patients, respectively; of these, 35 (70.0%) patients chose pembrolizumab, …

… The anti-PD-1 nivolumab and pembrolizumab, alone or in combination with ipilimumab,
provide higher response rates of approximately 40% and almost 60%, respectively, with the …

… administration of pembrolizumab. Changes in tumor size are commonly used to assess
treatment response and predict patient survival (4). However, changes in tumor size alone do not …

… delivery) in combination with pembrolizumab (200 mg Q3W, IV). Patients received a 1-week
lead-in dose of nintedanib monotherapy prior starting pembrolizumab. The primary objective …

… with pembrolizumab alone … pembrolizumab alone. Similar associations were observed with
survival in patients treated with pembrolizumab plus chemotherapy, despite the sample size …

Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial
carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of …

… volume provides a better prognostic determination for NSCLCs treated by pembrolizumab
than metabolic tumour volume alone… III–IV NSCLC with pembrolizumab alone in first line. The …